Introduction {#sec1_1}
============

Gastrointestinal mucosal injury is one of the most serious complications resulting from the conditioning regimens required for allogeneic hematopoietic stem cell transplantation (HSCT). It causes significant morbidity and may affect prognosis, because disruption of the gastrointestinal mucosal barrier facilitates translocation of microorganisms and/or endotoxins into the blood stream and increases mortality \[[@B1]\]. In this context, appropriate mitigation of gastrointestinal mucositis might improve the survival rate after HSCT.

Earlier studies comparing nutritional support with and without glutamine supplementation for patients with mucositis after HSCT were conducted because many investigators considered glutamine to be essential in critical illnesses such as radiation-induced colitis, sepsis, trauma, and burns \[[@B2], [@B3], [@B4]\]. These and other studies suggest that glutamine may exert a protective effect on the gut mucosal barrier and increase short-term survival after HSCT \[[@B5], [@B6], [@B7]\]. Standard total parenteral nutrition (TPN) does not contain glutamine because of its instability during heat sterilization and prolonged storage \[[@B8]\]. Additionally, glutamine for TPN, such as L-alanyl-L-glutamine dipeptide, is not available in Japan.

Both dietary fiber and oligosaccharide are also promising candidates for dietary supplements protecting against gastrointestinal mucosal injury induced by HSCT conditioning regimens. Dietary fiber plays an important role in controlling diarrhea, improving the restoration of bowel function, and reducing infection, thereby improving the prognosis of critically ill patients \[[@B9]\]. Oligosaccharide is thought to have beneficial effects by suppressing pathogenic bacteria in the colon \[[@B10]\]. Thus, the combination of glutamine, fiber and oligosaccharides (GFO) could be expected to protect against gastrointestinal mucosal injury in HSCT patients. Dietary fiber can also be fermented into short-chain fatty acids by bowel microflorae, which can protect the intestinal barrier and prevent bacterial translocation \[[@B9]\].

Currently, a commercial enteral GFO supplementation product is available in Japan. Recent investigations have revealed that this GFO preparation prevented gut bacterial translocation to the mesenteric lymph nodes in a murine model of bacterial overgrowth \[[@B11]\], and Joo et al. \[[@B9]\] reported that GFO has suppressive effects on mucosal damage in a murine ulcerative colitis model \[[@B12]\].

This study tests the hypothesis that enteral supplementation with GFO ameliorates gut injury induced by HSCT conditioning regimens and improves patient short-term survival in a retrospective analysis.

Patients and Methods {#sec1_2}
====================

Patients {#sec2_1}
--------

Patients who underwent stem cell transplantation at Sapporo Medical University Hospital between January 2009 and April 2011 were analyzed retrospectively with institutional review board approval. Patients were eligible for transplantation if they had any hematological malignancies at high risk for relapse and if suitable related or unrelated bone marrow/peripheral blood donors had been available within a reasonable period relative to their disease condition. Patients who had end-stage cardiac dysfunction (left ventricular ejection fraction \<35%), pulmonary dysfunction (SpO2 \<90% in room air), or active serious infection at the time of transplantation were not eligible. All patients gave written informed consent.

Conditioning Regimens and Graft-versus-Host Disease Prophylaxis {#sec2_2}
---------------------------------------------------------------

Conditioning regimens were either conventional or reduced-intensity conditioning (RIC) regimens. Conventional conditioning included the combination of busulfan 16 mg/kg and cyclophosphamide (CY) 120 mg/kg or total body irradiation 12 Gy and CY 120 mg/kg. RIC involved the use of fludarabine as a substitute for or in association with the conventional regimen drugs. Graft-versus-host disease (GVHD) prophylaxis regimens included the combination of FK506 and short-term methotrexate (MTX) or cyclosporine and short-term MTX. The first-line treatment for acute GVHD was prednisolone 1--2 mg/kg for all patients.

GFO administration {#sec2_3}
------------------

GFO was purchased from Otsuka Pharmaceutical Co., Ltd. (Tokushima, Japan). One pack of GFO (15 g) has 36 kcal and contains 3 g of glutamine, 5 g of dietary fiber, 1.5 g of oligosaccharide, and 1.2 mg of sodium. Two packages of GFO dissolved in 200 ml of water were administered to patients orally 3 times per day beginning 7 days prior to the start of conditioning and continued until 28 days after transplantation. Administration was stopped if vomiting occurred. TPN, conditioning chemotherapy, medication and transfusions were administered through a central venous catheter. While the neutrophil count remained \<0.5 × 10^9^/l, patients were nursed in reversed isolation.

Evaluation of Enteral Supplementation Enriched with GFO {#sec2_4}
-------------------------------------------------------

Diarrhea and oral mucositis were assessed using Common Terminology Criteria for Adverese Events (CTCAE) version 4.0. Diarrhea was classified as grade I when the incidence was below 4 episodes per day relative to baseline, as grade II when the incidence was 4--6 episodes per day over baseline, as grade III when the incidence was \>7 episodes per day over baseline, as grade IV when life-threatening consequences occurred, and as grade V when the patient died. Mucositis (oral) was classified as grade I when the patients was asymptomatic or only had mild symptoms (intervention not indicated), as grade II when moderate pain was experienced, not interfering with oral intake (modified diet indicated), as grade III when severe pain interfering with oral intake occurred, as grade IV when life-threatening consequences were found (urgent intervention indicated), and as grade V when the patient died. The mean and highest grades and durations were then calculated for analysis. The number of days and severity of diarrhea, mucositis, weight loss, fever (\>38.5 °C), TPN, episodes of microbiologically-documented infections, and hospital days were collected.

Selection of Matched Controls and Matching Variables {#sec2_5}
----------------------------------------------------

A matched-pair control group (no GFO supplement) for patients who used GFO was obtained from our historical database from 2006 to 2008. The controls were individually matched to the cases at a 1:1 ratio. Matching was attempted for the following criteria applied in the order they are listed: age at transplantation (\<55 vs. ≥55 years), ECOG performance status (0 or 1), disease status (standard vs. high risk; i.e. patients with acute leukemia, chronic myeloid leukemia, malignant lymphoma in complete remission, and myelodysplastic syndromes (refractory anemia) were categorized as standard risk, and all others as high risk), pretransplant conditioning (conventional vs. RIC), GVHD prophylaxis (FK-vs. cyclosporine-based), and graft source (bone marrow vs. peripheral blood). To avoid any potential selection bias, matching was blinded, and only the patients' ID and pretreatment variables were known.

Statistical Analysis {#sec2_6}
--------------------

Data were entered into a computerized database and analyzed by either Fisher\'s exact test or a χ^2^ test for categorical data and the Mann-Whitney U test for non-categorical data. The data analyzed between groups were as follows: (1) average diarrhea/mucositis score; (2) overall survival; (3) body weight loss; (4) febrile illness/documented infection; (5) intravenous hyperalimentation days/hospital days; (6) time to neutrophil engraftment; (7) incidences of acute and chronic GVHD, and (8) cumulative incidence of relapse.

The probabilities of overall survival were estimated and plotted using the Kaplan-Meier method. Data analysis was performed using GraphPad Prism version 5.0b (GraphPad Software Inc., San Diego, Calif., USA). The level of significance in all cases was set at p \< 0.05.

Results {#sec1_3}
=======

Patient Characteristics {#sec2_7}
-----------------------

Twenty-two patients who underwent stem cell transplantation and received GFO supplementation were analyzed. A matched-pair control group (no GFO supplementation) was obtained from our historical database. The characteristics of these two groups are summarized in table [1](#T1){ref-type="table"}. There was no difference between them with regard to sex (p = 0.75), age (p = 0.53), ECOG performance status (p = 0.62), underlying diagnoses (p = 0.55), disease status (p = 1.0), conditioning regimen (p = 0.93), GVHD prophylaxis (p = 0.66), and graft source (p = 1.0).

Clinical Outcomes {#sec2_8}
-----------------

Clinical outcomes are shown in table [2](#T2){ref-type="table"}. There were no differences in the maximum diarrhea (p = 0.68) or mucositis (p = 0.20) grades. However, a statistically significant reduction in the number of days of diarrhea grade 3--4 (p = 0.001) or grade 2 (p = 0.0001) and days of mucositis grade 3--4 (p = 0.033) was apparent in the GFO-supplemented group. GFO administration also prevented weight loss (p \< 0.001) and reduced the number of days of intravenous hyperalimentation (p = 0.001). There were no differences in the number of days with fever (\>38.5 °C; p = 0.41) or microbiologically-documented infections (p = 0.71), all of which were bloodstream infections: 3 methicillin-resistant *Staphylococcus aureus* (MRSA) and 1 methicillin-resistant *Staphylococcus epidermidis* (MRSE) in the GFO group, and 2 *Enterococcus faecium*, 1 *Enterococcus faecalis*, 1 methicillin-resistant *S. aureus*, and 1 methicillin-resistant *S. epidermidis* in the group without GFO supplementation. GFO administration did not affect the number of hospital days (p = 0.88). Next, we analyzed the impact of GFO on clinical parameters of HSCT, especially the time to engraftment, incidence and severity of acute/chronicGVHD and relapse rate. We found no differences between the two groups in this respect (data not shown). However, an apparent benefit was observed in the GFO group regarding the survival rate 100 days after HSCT (100 vs. 77.3%, p = 0.0091, log-rank test) as shown in figure [1](#F1){ref-type="fig"}. There were 5 deaths during the first 100 days after HSCT in the group without GFO due to refractory disease in 2 cases, sepsis in 2 cases, and pneumonia in 1 case. Median survival time was 530 versus 416 days (p = 0.6871) in the GFO and non-GFO group, respectively.

Discussion {#sec1_4}
==========

In the present study, we documented the beneficial effects of GFO in protecting against mucosal injury, decreasing weight loss and days of intravenous hyperalimentation, and increasing short-term survival after HSCT (table [2](#T2){ref-type="table"}; fig. [1](#F1){ref-type="fig"}). Conditioning chemotherapy and irradiation for HSCT evoke severe diarrhea and this adversely affected early therapy-related mortality. We observed that severe diarrhea was particularly improved in the GFO-supplemented group. Thus, it was considered that a reduction of therapy-related early mortality had been achieved. In fact, there were 2 patients who died from *Entercoccus* species infection due to bacterial translocation in the early phase after HSCT in the non-GFO group, although GFO supplementation neither suppressed the incidence of documented infection nor shortened the febrile period (table [2](#T2){ref-type="table"}). However, gut bacterial translocation, such as that of *Enterococcus* species *(E. faecium* or *E. faecalis)*, tended not to develop in the GFO group (p = 0.0728 relative to the control group). This suggested that GFO supplementation reduces gut mucosal injury and sepsis caused by enterococci in HSCT patients. Oligosaccharides included in GFO are prebiotics which have beneficial effects on commensal bacteria. Furthermore, we used a lactobacillus preparation (Biofermin-R, Biofermin Pharmaceutical Co. Ltd., Japan) as a probiotic in all patients. Since we observed mucosal injury less frequent and of shorter duration, we conclude that GFO and probiotics have synergistic effects (i.e. they are so-called 'synbiotics') and were able to ameliorate mucosal injury caused by the conditioning regimen.

Contrasting observations regarding the efficacy of oral glutamine \[[@B13]\] for amelioration of chemotherapy-associated mucositis could be related to a different route and schedule of glutamine administration in those studies. Anderson et al. \[[@B1]\] reported the efficacy of low-dose oral glutamine on oral mucosal injury during autologous bone marrow transplantation \[[@B14]\]. The dose of glutamine used in our study is comparatively higher than the average dietary intake (2--5 g/day) and almost the same as used by Anderson et al. A 2-gram oral dose of glutamine can significantly raise (0.1 mM difference) blood glutamine levels for about 1 h \[[@B15]\]. Since GFO contains 3 g of glutamine per pack, effects seen with the dose used in our study may be related to absorbed glutamine. Patients on GFO received an average of 32.4 g (2.16 per pack) per day, containing 6.48 g of glutamine, 10.8 g of dietary fiber, and 3.24 g of oligosaccharide. In the present study, using a relatively high dose of glutamine, fiber, and oligosaccharide, no GFO-related toxicity was found. GFO supplementation was well tolerated by the patients, and no allergic reactions were documented.

Oral glutamine appears to reduce GVHD and i.v. glutamine may increase the risk of relapse, according to a meta-analysis of studies of glutamine supplementation \[[@B7]\]. In our study, GFO supplementation neither suppressed the incidence of acute or chronic GVHD nor increased the relapse rate. However, these findings are based on a small number of patients. For definitive conclusions, larger well-designed prospective trials are required.

To the best of our knowledge, this is the first retrospective comparative clinical study of mucosal injury in allogeneic stem cell transplantation using GFO. We conclude that GFO supplementation is an effective supportive therapy to decrease the severity of mucosal injury in HSCT, which is a cause of morbidity associated with this treatment. Comparison of GFO with glutamine alone is planned for the future.
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###### 

Characteristics of transplant recipients

  Characteristics             Patients        p             
  --------------------------- --------------- ------------- --------
  *Sex*                                                     0.7470
  Male                        16              14            
  Female                      06              08            
                                                            
  *Age, years*                                              0.5256
  Median (range)              52.5 (21--62)   47 (19--62)   
                                                            
  *Age distribution, years*                                 1.0
  \<55                        05 (23)         05 (23)       
  ≥55                         17 (77)         17 (77)       
                                                            
  ECOG performance status                     0.6163        
  0                           21 (95)         20 (91)       
  1                           01 (5)          02 (9)        
                                                            
  *Diagnosis*                                               0.5540
  AML                         09 (41)         09 (41)       
  MDS                         05 (23)         04 (18)       
  ALL                         04 (18)         03 (14)       
  CML                         01 (5)          00 (0)        
  CLL                         01 (5)          00 (0)        
  ML                          01 (5)          05 (23)       
  MPD                         01 (5)          01 (5)        
                                                            
  *Disease status*                                          1.0
  Standard risk               10 (45)         11 (50)       
  High risk                   12 (55)         11 (50)       
                                                            
  *Conditioning*                                            0.9308
  Conventional                                              
   CY+TBI                     05              04            
   BU+CY                      02              02            
  RIC (Flu based)             15              16            
                                                            
  *GVHD prophylaxis*                                        0.6640
  FK506 + MTX                 18              20            
  CSP + MTX                   04              02            
                                                            
  *Graft source*                                            1.0
  Bone marrow                 21              21            
  Peripheral blood            01              01            

Values are presented as n (%) or median (range). AML = Acute myeloid leukemia; MDS = myelodysplastic syndromes; ALL = acute lymphoblastic leukemia; CML = chronic myeloid leukemia; CLL = chronic lymphocytic leukemia; ML = malignant lymphoma; MPD = myeloproliferative diseases; TBI = total body irradiation; BU = busulfan; Flu = fludarabine; CSP = cyclosporine.

###### 

Clinical outcomes

                                                     GFO               Non-GFO           \<p
  -------------------------------------------------- ----------------- ----------------- ----------
  Diarrhea grade (max. grade score)                  02.00             02.68             \<0.0677
   Days of diarrhea grade \>3                        00.86             03.27             \<0.0009
   Days of diarrhea grade \>2                        03.73             07.68             \<0.0001
  Mucositis grade (max grade score)                  01.55             02.05             \<0.2000
   Days of mucositis grade \>3                       03.86             06.00             \<0.0330
  Body weight loss, kg                               02.15             06.42             \<0.0001
  Days of intravenous hyperalimentation              36.91 (0--125)    54.14 (21--82)    \<0.0014
  Days with fever (\>38.5 °C)                        00.73             01.41             \<0.4096
  Ratio of microbiologically documented infections   4/22              5/22              \<0.7086
  Hospital days                                      81.18 (39--148)   78.00 (24--127)   \<0.8787
